Health
Sinopharm’s potential Covid-19 vaccine triggers antibodies in clinical trials – PharmaLive
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The shot did not cause any serious side effects, according to a paper published on Thursday in the Journal of the American Medical Association (JAMA) by scientists who are part of Sinopharm and other China-based disease control authorities and research institutes.
The results were based on data from 320 healthy adults in Phase 1 and 2 trials.
The candidate triggered robust antibody responses in inoculated people, but it remained unknown if that was sufficient to prevent COVID-19 infection, res…
-
General7 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News16 hours agoRainbow Beach surfer’s untold 7/7 story
-
General23 hours agoParis opens River Seine for public swimming for first time since 1923
-
General22 hours agoWest Indies vs Australia live: Second Test, day three from Grenada